Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB07133 in unresectable hepatocellular carcinoma
NCT00073736Phase 2Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Sep 2003
- Primary completion
- Jul 2007
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of MB01733 in hepatocellular carcinoma (HCC) (5 arms), sponsored by Ligand Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Sep 2003; status: completed.
02
Drugs
MB01733
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00073736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073736.